{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:22:11Z","timestamp":1772212931863,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nrleng.2025.501933","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:16:57Z","timestamp":1766621817000},"page":"501933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations for the diagnosis, treatment, and follow-up of late-onset Pompe disease"],"prefix":"10.1016","volume":"41","author":[{"given":"C.","family":"Dom\u00ednguez-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.\u00c1.","family":"Barba Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Caballero Eraso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"de las Heras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Farrero Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3.","family":"Garc\u00eda-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hern\u00e1ndez-Voth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Juntas Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Le\u00f3n Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ley Martos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"L\u00f3pez-Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Muelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Paradas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pardo Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.I.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Pitarch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"D\u00edaz-Manera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2025.501933_bib0005","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/biom10091339","article-title":"Pompe disease: new developments in an old lysosomal storage disorder","volume":"10","author":"Meena","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.nrleng.2025.501933_bib0010","first-page":"3","article-title":"Advances in diagnosis and management of Pompe disease","volume":"24","author":"Davison","year":"2020","journal-title":"J Mother Child"},{"key":"10.1016\/j.nrleng.2025.501933_bib0015","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.nrleng.2025.501933_bib0020","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nrleng.2025.501933_bib0025","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s13023-022-02545-w","article-title":"Expert Group Consensus on early diagnosis and management of infantile-onset Pompe disease in the Gulf region","volume":"17","author":"Al Hassnan","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nrleng.2025.501933_bib0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.33588\/rn.5408.2012088","article-title":"Gu\u00eda cl\u00ednica de la enfermedad de Pompe de inicio tard\u00edo","volume":"54","author":"Barba-Romero","year":"2012","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2025.501933_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12883-015-0412-3","article-title":"Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group","volume":"15","author":"Al Jasmi","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0045","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/cjn.2016.37","article-title":"Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel","volume":"43","author":"Tarnopolsky","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nrleng.2025.501933_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.739931","article-title":"Recommendations for infantile-onset and late-onset Pompe disease: an Iranian consensus","volume":"12","author":"Fatehi","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0055","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s13023-022-02574-5","article-title":"Survey on the management of Pompe disease in routine clinical practice in Spain","volume":"17","author":"Dom\u00ednguez-Gonz\u00e1lez","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nrleng.2025.501933_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2013.03.002","article-title":"Screening for later-onset Pompe\u2019s disease in patients with paucisymptomatic hyperCKemia","volume":"109","author":"Spada","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nrleng.2025.501933_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/ijns10010003","article-title":"Light and shadows in newborn screening for lysosomal storage disorders: eight years of experience in northeast Italy","volume":"10","author":"Gragnaniello","year":"2023","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.nrleng.2025.501933_bib0070","first-page":"271","article-title":"Infantile-onset Pompe disease: diagnosis and management","volume":"117","author":"Bay","year":"2019","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.nrleng.2025.501933_bib0075","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/humu.23854","article-title":"Extension of the Pompe mutation database by linking disease-associated variants to clinical severity","volume":"40","author":"Ni\u00f1o","year":"2019","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nrleng.2025.501933_bib0080","unstructured":"Pompe disease GAA variant database. [Accessed 12 June 2024]. Available from: https:\/\/www.pompevariantdatabase.nl."},{"key":"10.1016\/j.nrleng.2025.501933_bib0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymgme.2007.09.006","article-title":"Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting","volume":"93","author":"Winchester","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nrleng.2025.501933_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163493","article-title":"Muscle MRI findings in childhood\/adult onset Pompe disease correlate with muscle function","volume":"11","author":"Figueroa-Bonaparte","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nrleng.2025.501933_bib0095","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/mus.27099","article-title":"Skeletal muscle magnetic resonance imaging in Pompe disease","volume":"63","author":"D\u00edaz-Manera","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2025.501933_bib0100","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/biom13091279","article-title":"A comprehensive update on late-onset Pompe disease","volume":"13","author":"Labella","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.nrleng.2025.501933_bib0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1590\/0004-282X20130022","article-title":"Muscle biopsy in Pompe disease","volume":"71","author":"Werneck","year":"2013","journal-title":"Arq de Neuro-Psiquiatria"},{"key":"10.1016\/j.nrleng.2025.501933_bib0110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.33588\/rn.6007.2015029","article-title":"Gu\u00eda para el seguimiento de la enfermedad de Pompe de inicio tard\u00edo","volume":"60","author":"Guti\u00e9rrez-Rivas","year":"2015","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0120","unstructured":"Leslie N, Bailey L. Pompe Disease. 2007. En: Adam MP, Feldman J, Mirzaa GM, et al., editores. GeneReviews\u00ae Seattle (WA): University of Washington, Seattle; 1993-2023. [Updated 2023 Nov 2] [Accessed 12 June 2024]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1261\/\/."},{"key":"10.1016\/j.nrleng.2025.501933_bib0125","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3390\/ijms17101735","article-title":"Practical recommendations for diagnosis and management of respiratory muscle weakness in late-onset Pompe disease","volume":"17","author":"Boentert","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nrleng.2025.501933_bib0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.arbres.2012.12.003","article-title":"Guidelines for the management of respiratory complications in patients with neuromuscular disease. Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR) [Article in English, Spanish]","volume":"49","author":"Farrero","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11325-015-1247-2","article-title":"Nocturnal hypoventilation in neuromuscular disease: prevalence according to different definitions issued from the literature","volume":"20","author":"Ogna","year":"2016","journal-title":"Sleep Breath"},{"key":"10.1016\/j.nrleng.2025.501933_bib0145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.166.4.518","article-title":"ATS\/ERS Statement on respiratory muscle testing","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nrleng.2025.501933_bib0150","first-page":"190","article-title":"Medici\u00f3n del grosor diafragm\u00e1tico como par\u00e1metro predictivo para retiro de ventilaci\u00f3n mec\u00e1nica invasiva en pacientes de terapia intensiva","volume":"31","author":"Tanaka Montoya","year":"2017","journal-title":"Med Crit"},{"key":"10.1016\/j.nrleng.2025.501933_bib0155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cnp.2020.01.001","article-title":"Thickening fraction as a measure of ultrasonographic diaphragm dysfunction in amyotrophic lateral sclerosis","volume":"5","author":"Digala","year":"2020","journal-title":"Clin Neurophysiol Pract"},{"key":"10.1016\/j.nrleng.2025.501933_bib0160","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.nrleng.2025.501933_bib0165","unstructured":"Agencia Europea del Medicamento. Myozyme, alglucosidase alfa [Accessed 3 October 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/myozyme-epar-product-information_es.pdfSource."},{"key":"10.1016\/j.nrleng.2025.501933_bib0170","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0175","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1095134","article-title":"Expert opinion on the diagnostic odyssey and management of late-onset Pompe disease: a neurologist\u2019s perspective","volume":"14","author":"Erdem Ozdamar","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.nrleng.2025.501933_bib0185","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2025.501933_bib0190","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0195","unstructured":"Ficha t\u00e9cnica Nexviadyme 100 mg (avalglucosidasa alfa). \u00daltima actualizaci\u00f3n 11 marzo 2024 [Accessed 3 October 2023]. Available from: https:\/\/www.ema.europa.eu\/es\/documents\/product-information\/nexviadyme-epar-product-information_es.pdf."},{"key":"10.1016\/j.nrleng.2025.501933_bib0200","series-title":"\u00daltima actualizaci\u00f3n 16 mayo 2023","year":"2023"},{"key":"10.1016\/j.nrleng.2025.501933_bib0205","series-title":"\u00daltima actualizaci\u00f3n 22 septiembre 2023","year":"2023"},{"key":"10.1016\/j.nrleng.2025.501933_bib0210","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0215","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.nrleng.2025.501933_bib0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-023-02981-2","article-title":"Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry","volume":"18","author":"Kishnani","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nrleng.2025.501933_bib0225","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.nrleng.2025.501933_bib0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"De Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nrleng.2025.501933_bib0235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nmd.2019.11.007","article-title":"Discontinuation of enzyme replacement therapy in adults with Pompe disease: evaluating the European POmpe Consortium stop criteria","volume":"30","author":"Van Kooten","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nrleng.2025.501933_bib0240","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/TCRM.S362871","article-title":"Monitoring and management of respiratory function in Pompe disease: current perspectives","volume":"19","author":"El Haddad","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nrleng.2025.501933_bib0245","first-page":"318","article-title":"Aspectos respiratorios y de fisioterapia pulmonar en el ni\u00f1o con mucopolisacaridosis","volume":"78","author":"Cruz-Anleu","year":"2021","journal-title":"Bol Med Hosp Infant Mex"},{"key":"10.1016\/j.nrleng.2025.501933_bib0250","first-page":"255","article-title":"Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness","volume":"7","author":"Jones","year":"2014","journal-title":"J Pediatr Rehabil Med"},{"key":"10.1016\/j.nrleng.2025.501933_bib0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-015-0303-0","article-title":"Safety and efficacy of exercise training in adults with Pompe disease: evaluation of endurance, muscle strength and core stability before and after a 12 week training program","volume":"10","author":"Van den Berg","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nrleng.2025.501933_bib0260","doi-asserted-by":"crossref","DOI":"10.22379\/anc.v39i2.1750","article-title":"Rehabilitaci\u00f3n en la enfermedad de Pompe","volume":"39","author":"Jaramillo-Herrera","year":"2023","journal-title":"Acta Neurol Colomb"},{"key":"10.1016\/j.nrleng.2025.501933_bib0265","unstructured":"UK Research and Innovation. MRC muscle scale [Accessed 12 Jan 2023]. Available from: https:\/\/www.ukri.org\/councils\/mrc\/facilities-and-resources\/find-an-mrc-facility-or-resource\/mrc-muscle-scale\/."},{"key":"10.1016\/j.nrleng.2025.501933_bib0270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nrleng.2025.501933_bib0275","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.nmd.2012.10.024","article-title":"The Rasch-built Pompe-specific Activity (R-Pact) scale","volume":"23","author":"Van der Beek","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nrleng.2025.501933_bib0280","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","article-title":"Reliability of the North Star Ambulatory Assessment in a multicentric setting","volume":"19","author":"Mazzone","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nrleng.2025.501933_bib0285","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ana.26044","article-title":"Assessing dysferlinopathy patients over three years with a new motor scale","volume":"89","author":"Jacobs","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrleng.2025.501933_bib0290","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/metabo11070446","article-title":"Experience with the urinary tetrasaccharide metabolite for Pompe disease in the diagnostic laboratory","volume":"11","author":"Saville","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.nrleng.2025.501933_bib0295","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/thx.2010.139782","article-title":"Nocturnal monitoring of home non-invasive ventilation: the contribution of simple tools such as pulse oximetry, capnography, built-in ventilator software and autonomic markers of sleep fragmentation","volume":"66","author":"Janssens","year":"2011","journal-title":"Thorax"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082500121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082500121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:31:08Z","timestamp":1772209868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S217358082500121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S217358082500121X"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2025.501933","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the diagnosis, treatment, and follow-up of late-onset Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2025.501933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2025.501933","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501933"}}